A shorter time interval is indicated if the baseline serum creatinine is high, or serum potassium is already high-normal, or there is a history of hyperkalemia or an acute rise in serum creatinine with BP lowering or RASi. Practice Point 3.2.4: Hyperkalemia associated with use of RASi can often be managed by measures to reduce the serum potassium levels rather than decreasing the dose or stopping RASi. In observational cohorts, hyperkalemia is often associated with a subsequent reduction in dose or discontinuation of Pseudo-hyperkalemia needs to be rst ruled out. Then, there are multiple measures that can be taken to mitigate the hyperkalemia.44 Improvement in potassium control could lead to increased use of RASi in patients with an evidence-based indication. Strategies to control chronic hyperkalemia include dietary potassium restriction; discon- tinuation of potassium supplements, certain salt substitutes, and hyperkalemic drugs; adding potassium-wasting diuretics, and oral potassium binders.44 In CKD patients receiving RASi who develop hyperkalemia, the latter can be controlled with newer oral potassium binders in many patients, with the ef- fect that RASi can be continued at the recommended Whether the latter therapeutic strategy improves CV or kidney outcomes is being examined in RCTs, such as the ongoing DIAMOND trial (NCT03888066). Side effects of the newer potassium binders are reported to be moderate. Practice Point 3.2.5: Continue ACEi or ARB therapy unless serum creatinine rises by more than 30% within 4 weeks following initiation of treatment or an increase in dose. This practice point reiterates a common expert opinion and may be a reasonable option for many patients treated with RASi. 